Version history

{
  "session_id": "sess-hyp-78891e7dfa87",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Translational Assessment: ACSL4-Driven Ferroptotic Priming in AD-Associated White Matter Degeneration\n\n## Executive Summary\n\nThis hypothesis presents a mechanistically compelling yet speculative target for Alzheimer's disease intervention. While ACSL4 is a druggable enzyme with established roles in ferroptosis, significant translational gaps exist between the current preclinical evidence and a viable therapeutic strategy. The hypothesis benefits from strong biological plausibility but lacks direct pharmacological validation in AD-relevant models.\n\n---\n\n## 1. TARGET DRUGGABILITY ASSESSMENT\n\n| Criterion | Assessment | Confidence |\n|-----------|------------|------------|\n| **Enzyme Class** | ATP-dependent ligase (ACSL family) | High |\n| **Active Site Tractability** | Well-defined CoA/ATP binding pockets | Moderate |\n| **Selectivity Challenge** | 6 ACSL isoforms (ACSL1,3,4,5,6) with overlapping substrate specificity | High concern |\n| **CNS Penetration** | Essential for any AD indication | Critical unknown |\n| **Gene Family Complexity** | Functional redundancy may limit efficacy and increase toxicity | Significant concern |\n\n**Key Druggability Issues:**\n- ACSL4 shares ~70% catalytic domain homology with other ACSL family members\n- Isoform-selective inhibition has proven technically challenging with small molecules\n- Knockout studies show compensatory upregulation of ACSL1 in some contexts\n- Blood-brain barrier penetration remains entirely unaddressed\n\n**Druggability Score: 0.55** (Moderate - enzyme is tractable but selectivity/CNS delivery are major hurdles)\n\n---\n\n## 2. EXISTING TOOL COMPOUNDS\n\n### Direct ACSL4 Inhibitors\n| Compound | Evidence Quality | Limitations |\n|----------|------------------|--------------|\n| **Rosiglitazone** | In vitro biochemical studies; inhibits ACSL4 at μM concentrations | Non-selective (PPARγ agonist); thiazolidinedione class has known safety liabilities |\n| **Thiazolidinedione analogs** | Some SAR studies exist | Not CNS-penetrant; off-target effects |\n| **ACG-110** | Reported ACSL4-selective inhibitor | Limited publication; unverified activity in vivo |\n\n### Indirect Ferro",
  "tokens_used": "535",
  "persona_id": "persona-domain_expert"
}